Ohio State University CRS

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• HIV8 trials
• Depression1 trial
• Hepatitis B1 trial
• Lung cancer1 trial
• Ovarian cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 33 trials
• Phase 12 trials
• Phase 1/22 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Completed4 trials
• Suspended3 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• National Institute of Allergy and Infectious Diseases (NIAID)8 trials
• Gilead Sciences2 trials

Running trials

• Not yet recruiting

  A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

  NCT06987318· Phase 1· National Institute of Allergy and Infectious Diseases (NIAID)· Source

  Contact: Lindsay Summers

• Recruiting

  FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  NCT06303505· Phase 1/2· Gilead Sciences· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

  NCT04193189· Phase 3· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

  NCT03739996· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

  NCT03635788· Phase 3· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

  NCT02720094· Phase 2/3· National Institute of Allergy and Infectious Diseases (NIAID)· Source